中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 4
Apr.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(4): 773-777

The role of gut microbiota in acute kidney injury in patients with decompensated liver cirrhosis and related targeted therapies

DOI: 10.12449/JCH250426
  • 1.

    Department of Infectious and Center for Liver Diseases，Peking University First Hospital，Beijing 100034，China

  • 2.

    Department of Hepatology，Mengchao Hepatobiliary Hospital of Fujian Medical University，Fuzhou 350002，China

  • 3.

    Department of Infectious Disease，Peking University International Hospital，Beijing 102206，China

Research funding:

Natural Science Foundation of Fujian Province (2023J011461)

More Information
  • Corresponding author: WANG Guiqiang， john131212@126.com （ORCID： 0000-0002-0317-7536）
  • Received Date: 2024-07-25
  • Accepted Date: 2024-09-05
  • Published Date: 2025-04-25
    Abstract
  • Acute kidney injury （AKI） is a severe complication in patients with decompensated liver cirrhosis and tends to have a high mortality rate and a poor prognosis. Current studies have shown that gut microbiota might be associated with the development and progression of AKI， and it is necessary to pay attention to the application of targeted therapy based on gut microbiota in the prevention and treatment of such patients. Therefore， this article reviews the possible pathogenesis of gut microbiota in liver cirrhosis comorbid with AKI， as well as potential prevention and treatment measures targeting gut microbiota， in order to provide a reference for the pathogenesis of such patients and related treatment methods.

     

    • FullText(HTML)
  • loading
    • References(38)
  • [1]
    NADIM MK, GARCIA-TSAO G. Acute kidney injury in patients with cirrhosis[J]. N Engl J Med, 2023, 388( 8): 733- 745. DOI: 10.1056/NEJMra2215289.
    [2]
    DESAI AP, KNAPP SM, ORMAN ES, et al. Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis- a US population-based study[J]. J Hepatol, 2020, 73( 5): 1092- 1099. DOI: 10.1016/j.jhep.2020.04.043.
    [3]
    TANDON P, JAMES MT, ABRALDES JG, et al. Relevance of new definitions to incidence and prognosis of acute kidney injury in hospitalized patients with cirrhosis: A retrospective population-based cohort study[J]. PLoS One, 2016, 11( 8): e0160394. DOI: 10.1371/journal.pone.0160394.
    [4]
    MOHAN PB, NAGARAJU SP, MUSUNURI B, et al. Study of prevalence, risk factors for acute kidney injury, and mortality in liver cirrhosis patients[J]. Ir J Med Sci, 2024, 193( 4): 1817- 1825. DOI: 10.1007/s11845-024-03663-z.
    [5]
    SIMONETTO DA, GINES P, KAMATH PS. Hepatorenal syndrome: Pathophysiology, diagnosis, and management[J]. BMJ, 2020, 370: m2687. DOI: 10.1136/bmj.m2687.
    [6]
    FRANCOZ C, DURAND F, KAHN JA, et al. Hepatorenal syndrome[J]. Clin J Am Soc Nephrol, 2019, 14( 5): 774- 781. DOI: 10.2215/cjn.12451018.
    [7]
    SHAH N, DHAR D, ZAHRAA MOHAMMED F EL, et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression[J]. J Hepatol, 2012, 56( 5): 1047- 1053. DOI: 10.1016/j.jhep.2011.11.024.
    [8]
    ZHANG LL, HU JH, DAI XC, et al. Research progress on the relationship between cirrhotic ascites and intestinal mucosal barrier function[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 2): 23- 27. DOI: 10.3969/j.issn.1674-7380.2023.02.005.

    张丽丽, 胡建华, 代欣璨, 等. 肝硬化腹水与肠黏膜屏障功能关系研究进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 2): 23- 27. DOI: 10.3969/j.issn.1674-7380.2023.02.005.
    [9]
    JO SK, CHA DR, CHO WY, et al. Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells[J]. Nephron, 2002, 91( 3): 406- 415. DOI: 10.1159/000064280.
    [10]
    OHIRA H, TSUTSUI W, FUJIOKA Y. Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis?[J]. J Atheroscler Thromb, 2017, 24( 7): 660- 672. DOI: 10.5551/jat.RV17006.
    [11]
    JIN ML, KALAINY S, BASKOTA N, et al. Faecal microbiota from patients with cirrhosis has a low capacity to ferment non-digestible carbohydrates into short-chain fatty acids[J]. Liver Int, 2019, 39( 8): 1437- 1447. DOI: 10.1111/liv.14106.
    [12]
    GHARAIE S, NOEL S, RABB H. Gut microbiome and AKI: Roles of the immune system and short-chain fatty acids[J]. Nephron, 2020, 144( 12): 662- 664. DOI: 10.1159/000508984.
    [13]
    ANDRADE-OLIVEIRA V, AMANO MT, CORREA-COSTA M, et al. Gut bacteria products prevent AKI induced by ischemia-reperfusion[J]. J Am Soc Nephrol, 2015, 26( 8): 1877- 1888. DOI: 10.1681/ASN.2014030288.
    [14]
    AL-HARBI NO, NADEEM A, AHMAD SF, et al. Short chain fatty acid, acetate ameliorates sepsis-induced acute kidney injury by inhibition of NADPH oxidase signaling in T cells[J]. Int Immunopharmacol, 2018, 58: 24- 31. DOI: 10.1016/j.intimp.2018.02.023.
    [15]
    VELDEMAN L, VANMASSENHOVE J, van BIESEN W, et al. Evolution of protein-bound uremic toxins indoxyl sulphate and p-cresyl sulphate in acute kidney injury[J]. Int Urol Nephrol, 2019, 51( 2): 293- 302. DOI: 10.1007/s11255-018-2056-x.
    [16]
    LEE TH, PARK D, KIM YJ, et al. Lactobacillus salivarius BP121 prevents cisplatin-induced acute kidney injury by inhibition of uremic toxins such as indoxyl sulfate and p-cresol sulfate via alleviating dysbiosis[J]. Int J Mol Med, 2020, 45( 4): 1130- 1140. DOI: 10.3892/ijmm.2020.4495.
    [17]
    WANG WJ, HAO GH, PAN Y, et al. Serum indoxyl sulfate is associated with mortality in hospital-acquired acute kidney injury: A prospective cohort study[J]. BMC Nephrol, 2019, 20( 1): 57. DOI: 10.1186/s12882-019-1238-9.
    [18]
    LIN CJ, LIOU TC, PAN CF, et al. The role of liver in determining serum colon-derived uremic solutes[J]. PLoS One, 2015, 10( 8): e0134590. DOI: 10.1371/journal.pone.0134590.
    [19]
    RICHARD ML, SOKOL H. The gut mycobiota: Insights into analysis, environmental interactions and role in gastrointestinal diseases[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 6): 331- 345. DOI: 10.1038/s41575-019-0121-2.
    [20]
    TRANAH TH, EDWARDS LA, SCHNABL B, et al. Targeting the gut-liver-immune axis to treat cirrhosis[J]. Gut, 2021, 70( 5): 982- 994. DOI: 10.1136/gutjnl-2020-320786.
    [21]
    ALBILLOS A, DE GOTTARDI A, RESCIGNO M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72( 3): 558- 577. DOI: 10.1016/j.jhep.2019.10.003.
    [22]
    NIE GL, ZHANG HL, XIE DN, et al. Liver cirrhosis and complications from the perspective of dysbiosis[J]. Front Med(Lausanne), 2024, 10: 1320015. DOI: 10.3389/fmed.2023.1320015.
    [23]
    WU ZR, ZHOU HJ, LIU DL, et al. Alterations in the gut microbiota and the efficacy of adjuvant probiotic therapy in liver cirrhosis[J]. Front Cell Infect Microbiol, 2023, 13: 1218552. DOI: 10.3389/fcimb.2023.1218552.
    [24]
    LUAN YT, LIU CH, JIANG SL, et al. Comparative analysis of intestinal microbiota distribution characteristics based on metagenomics in patients with hepatitis B cirrhosis with or without ascites[J]. Chin J Hepatol, 2023, 31( 9): 974- 985. DOI: 10.3760/cma.j.cn501113-20220830-00440.

    栾雨婷, 刘成海, 蒋式骊, 等. 基于宏基因组学比较分析乙型肝炎肝硬化伴或不伴腹水患者肠道菌群的分布特征[J]. 中华肝脏病杂志, 2023, 31( 9): 974- 985. DOI: 10.3760/cma.j.cn501113-20220830-00440.
    [25]
    YOUSSEF AL-OKBI S, ABDOU MOHAMED D, EL-SAYED HAMED T, et al. Role of probiotic mixture with and without green tea extract in prevention of hepatorenal syndrome in rat model[J]. Pak J Biol Sci, 2019, 22( 1): 21- 27. DOI: 10.3923/pjbs.2019.21.27.
    [26]
    PATEL VC, LEE S, MCPHAIL MJW, et al. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial[J]. J Hepatol, 2022, 76( 2): 332- 342. DOI: 10.1016/j.jhep.2021.09.010.
    [27]
    ELFERT A, ABO ALI L, SOLIMAN S, et al. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis[J]. Eur J Gastroenterol Hepatol, 2016, 28( 12): 1450- 1454. DOI: 10.1097/MEG.0000000000000724.
    [28]
    ZENG X, SHENG X, WANG PQ, et al. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis[J]. Hepatol Int, 2021, 15( 1): 155- 165. DOI: 10.1007/s12072-020-10117-y.
    [29]
    BUREAU C, THABUT D, JEZEQUEL C, et al. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled trial[J]. Ann Intern Med, 2021, 174( 5): 633- 640. DOI: 10.7326/M20-0202.
    [30]
    IBRAHIM ES, ALSEBAEY A, ZAGHLA H, et al. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome[J]. Eur J Gastroenterol Hepatol, 2017, 29( 11): 1247- 1250. DOI: 10.1097/MEG.0000000000000967.
    [31]
    DONG TE, ARONSOHN A, GAUTHAM REDDY K, et al. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis[J]. Dig Dis Sci, 2016, 61( 12): 3621- 3626. DOI: 10.1007/s10620-016-4313-0.
    [32]
    HU YC, DING XC, LIU HJ, et al. Effects of Lactobacillus paracasei N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis[J]. World J Gastroenterol, 2024, 30( 11): 1556- 1571. DOI: 10.3748/wjg.v30.i11.1556.
    [33]
    CHÁVEZ-ÍÑIGUEZ JS, IBARRA-ESTRADA M, GALLARDO-GONZÁLEZ AM, et al. Probiotics in septic acute kidney injury, a double blind, randomized control trial[J]. Ren Fail, 2023, 45( 2): 2260003. DOI: 10.1080/0886022X.2023.2260003.
    [34]
    TREBICKA J, MACNAUGHTAN J, SCHNABL B, et al. The microbiota in cirrhosis and its role in hepatic decompensation[J]. J Hepatol, 2021, 75( Suppl 1): S67- S81. DOI: 10.1016/j.jhep.2020.11.013.
    [35]
    BAJAJ JS, GAVIS EA, FAGAN A, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder[J]. Hepatology, 2021, 73( 5): 1688- 1700. DOI: 10.1002/hep.31496.
    [36]
    BAJAJ JS, SALZMAN N, ACHARYA C, et al. Microbial functional change is linked with clinical outcomes after capsular fecal transplant in cirrhosis[J]. JCI Insight, 2019, 4( 24): e133410. DOI: 10.1172/jci.insight.133410.
    [37]
    XU HK, WANG CF, ZHANG Y, et al. Role of fecal microbiota transplantation in chronic liver diseases[J]. J Clin Hepatol, 2023, 39( 9): 2237- 2243. DOI: 10.3969/j.issn.1001-5256.2023.09.031.

    徐洪凯, 汪春付, 张野, 等. 粪菌移植在慢性肝病治疗中的应用[J]. 临床肝胆病杂志, 2023, 39( 9): 2237- 2243. DOI: 10.3969/j.issn.1001-5256.2023.09.031.
    [38]
    RAJ D, TOMAR B, LAHIRI A, et al. The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease[J]. Pharmacol Res, 2020, 152: 104617. DOI: 10.1016/j.phrs.2019.104617.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (424) PDF downloads(32) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return